Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

Minimal residual disease (MRD) is associated with adverse outcome in AML after myeloablative (MA) hematopoietic cell transplantation (HCT). We compared this association with that seen after nonmyeloablative (NMA) conditioning in 241 adults receiving NMA (n=86) or MA (n=155) HCT for AML in first remi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia
Hauptverfasser: Walter, Roland B., Gyurkocza, Boglarka, Storer, Barry E., Godwin, Colin D., Pagel, John M., Buckley, Sarah A., Sorror, Mohamed L., Wood, Brent L., Storb, Rainer, Appelbaum, Frederick R., Sandmaier, Brenda M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4254901/
https://ncbi.nlm.nih.gov/pubmed/24888275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2014.173
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge